Holen Sie sich die Stockscreener-App
10.04
1.93%
0.19
Schlusskurs vom Vortag:
$9.85
Offen:
$9.85
24-Stunden-Volumen:
616.94K
Relative Volume:
0.74
Marktkapitalisierung:
$532.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.44M
KGV:
-11.27
EPS:
-0.8906
Netto-Cashflow:
$-24.66M
1W Leistung:
+14.74%
1M Leistung:
+0.40%
6M Leistung:
+283.21%
1J Leistung:
+497.62%
1-Tages-Spanne:
$9.73
$10.16
1-Wochen-Bereich:
$8.69
$10.16
52-Wochen-Spanne:
$1.57
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
10.04 | 522.17M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2026-02-09 | Eingeleitet | Mizuho | Outperform |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma (IMMX) price target increased by 11.73% to 18.62 - MSN
Moving Averages: Should I trade or invest in Immix Biopharma IncWall Street Watch & Precise Swing Trade Alerts - baoquankhu1.vn
IMMX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bear Alert: Is Immix Biopharma Inc in a bullish channel2026 Analyst Calls & Weekly High Conviction Ideas - baoquankhu1.vn
Guidance Update: Is Immix Biopharma Inc stock a buy or sell2026 Bull vs Bear & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy - MSN
Immix Biopharma to Participate in Jefferies Global Healthcare Conference - National Today
Immix Biopharma to Host Investor Meetings at Jefferies Global Healthcare Conference 2026 - Quiver Quantitative
Immix Biopharma lines up investor meetings at Jefferies event - Stock Titan
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Bitget
Immix Biopharma (IMMX) seeks approval of board slate, auditor and reviews 2025 executive pay - Stock Titan
Earnings Recap: Is Immix Biopharma Inc benefiting from innovation trendsNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - stockinvest.us
Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation - MSN
IMMX PE Ratio & Valuation, Is IMMX Overvalued - Intellectia AI
Immix Biopharma ― NEXICART-2 の進展で勢いが増す - Smartkarma
Weekly Earnings: Is Immix Biopharma Inc stock a buy or sell2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Bear Alert: Is Immix Biopharma Inc benefiting from innovation trends2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Citizens reiterates Immix Biopharma stock rating on trial enrollment By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com
Immix Biopharma completes enrollment in AL amyloidosis trial By Investing.com - Investing.com South Africa
Immix Biopharma (IMMX) price target increased by 25.64% to 16.66 - MSN
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201 - tipranks.com
Immix completes enrollment in NEXICART-2; topline results expected Q3 2026 - TradingView
[8-K] Immix Biopharma, Inc. Reports Material Event - stocktitan.net
Immix Biopharma Completes Enrollment for Key AL Amyloidosis Trial - nationaltoday.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming Milestones - marketscreener.com
Immix Biopharma completes enrollment in AL amyloidosis trial - Investing.com
Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA). - Bitget
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - The Manila Times
Mizuho raises Immix Biopharma stock price target on cash position By Investing.com - Investing.com India
Mizuho raises Immix Biopharma stock price target on cash position - Investing.com
Should I trade or invest in Immix Biopharma Inc2026 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Immix Biopharma, Inc. 2025 Annual Report Amendment: Financial Statements, Auditor Correction, and Company Overview - Minichart
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) widens 2025 loss but ends year with $100M cash - stocktitan.net
Mizuho raises Immix Biopharma stock price target to $15 on cash position - Investing.com Australia
Mizuho raises Immix Biopharma stock price target to $15 on cash position By Investing.com - Investing.com South Africa
Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):